GET DAILY SIGNALSWhy Is Nurix Therapeutics (NRIX) Stock Down -41.21% Today?
Key Takeaways
- Nurix Therapeutics (NRIX) shares plunged roughly 41% in Tuesday's session after partner Sanofi terminated a key drug program.
- The primary catalyst was Sanofi's decision to discontinue the Phase 1 trial of SAR448272, an oral STAT6 degrader, and end the program entirely.
- The termination removes NRIX's expected future milestone payments and royalties tied to SAR448272 under the 2019 collaboration.
- The company stressed that its $1.1 billion cash position and runway into the second half of 2029 are unchanged, and that its other partnered programs remain intact.
- Broader biotech sentiment was mixed, but the move was clearly stock-specific and driven by the program termination rather than sector or macro forces.
- Traders are now watching for analyst reactions, any reassessment of the Sanofi collaboration's remaining value, and updates on Nurix's three clinical-stage programs.
- For more detail on Price Targets, Earnings, and Forecast data, explore Tickeron's dedicated pages for this ticker.
- Discover how AI-driven trading strategies are navigating volatile biotech names on Tickeron's Trending AI Robots page.
Opening Summary
Nurix Therapeutics, Inc. (NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines for cancer and autoimmune diseases, saw its shares fall sharply in Tuesday's session. The stock traded down about 41% intraday to around $15.18, compared with a prior session close of $25.82. The selloff followed Sanofi's announcement that it would discontinue development of SAR448272, an oral STAT6 degrader licensed under the companies' collaboration agreement, eliminating a meaningful source of anticipated future milestone and royalty payments.
Sanofi Discontinues the STAT6 Degrader Program
The decisive catalyst behind the decline was Sanofi's notification that it will discontinue the Phase 1 first-in-human trial of SAR448272 and terminate the program altogether. Under the 2019 collaboration, Nurix had deployed its DEL-Al drug discovery platform to identify degraders, and Sanofi had exercised a license extension option in 2025 covering the STAT6 program for autoimmune and inflammatory diseases. With the program now cancelled, Nurix does not expect to receive the future development, regulatory, and commercial milestone payments or royalties tied to SAR448272, a material setback for the stock's long-term revenue expectations.
The market reaction reflects the removal of a potential value driver rather than any deterioration in Nurix's broader fundamentals. Nurix retains eligibility for milestone payments and royalties from other licensed programs under the Sanofi collaboration, and management emphasized that the decision does not change its cash runway guidance.
Why the Core Pipeline Still Matters
Despite the disappointing news, Nurix maintains three clinical-stage programs across its wholly owned and partnered portfolio. Its lead BTK degrader, Rexobrutide (also referred to as bexobrutideg), is advancing in a Phase 3 trial in chronic lymphocytic leukemia in collaboration with Roche. Its wholly owned CBL-B inhibitor, NX-1607, is progressing through multiple Phase 1b cohorts for lung, colon, prostate, and skin cancers, while the IRAK4 degrader GS-6791/NX-0479 is in Phase 1 trials for rheumatoid arthritis with partner Gilead. The company also reported $1.1 billion in cash, equivalents, and marketable securities as of August 31, 2026, which it says funds operations into the second half of 2029.
Market Context and Trading Activity
The decline in NRIX was driven overwhelmingly by company-specific news rather than broad sector or index movements. Nurix had been a strong performer through the year, up more than 30% in 2026 and over 100% on a trailing 12-month basis before the announcement, leaving the stock vulnerable to a sharp repricing when a key partnered asset was removed from the pipeline. Trading volume was heavy relative to the stock's typical daily average, consistent with institutional repositioning following the news. The move pulled the shares well below recent trading ranges established in the high-$20s, erasing a large portion of the year's gains in a single session.
What Comes Next for NRIX
Investors will be watching for analyst commentary on the revised value of the Sanofi collaboration and any adjustments to ratings or models that incorporate the lost SAR448272 economics. Near-term attention will also focus on clinical updates across Rexobrutide, NX-1607, and the Gilead-partnered IRAK4 program, as these assets now carry greater weight in the investment thesis. Upcoming earnings, scheduled for late January, will provide further detail on cash runway and development plans. Key risks include additional pipeline setbacks, regulatory hurdles across its clinical programs, and the possibility that sentiment around targeted protein degradation remains volatile following the Sanofi decision.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots from a broader universe of hundreds of strategies covering thousands of tickers. Only the strongest performers under current market conditions are featured, with bots differing by strategy, timeframe, performance metrics, and the symbols they trade. Explore the page to see how these automated systems are adapting to fast-moving market events.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for NRIX turns negative, indicating new downward trend
NRIX saw its Momentum Indicator move below the 0 level on November 03, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In 78 of the 85 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for NRIX moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 21 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 51 cases where NRIX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
NRIX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NRIX entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for NRIX just turned positive on October 14, 2026. Looking at past instances where NRIX's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
NRIX moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NRIX crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRIX advanced for three days, in 203 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. NRIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.655) is normal, around the industry mean (3.051). P/E Ratio (-7.462) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (68.493) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders
Industry Biotechnology
Advertisement